Summary
Pharmaceuticals in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Indonesian pharmaceuticals market had total revenues of $7.1m in 2018, representing a compound annual growth rate (CAGR) of 8.3% between 2014 and 2018.
- The performance of the market is forecast to accelerate, with an anticipated CAGR of 10.3% for the five-year period 2018-2023, which is expected to drive the market to a value of $11.6m by the end of 2023.
- The market is anticipates to grow at a significant weight, and the lifting of restrictions on foreign ownership and concurrent measures undertaken by the government are underpinning future economic growth.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Indonesia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Indonesia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia pharmaceuticals market with five year forecasts
Reasons to buy
- What was the size of the Indonesia pharmaceuticals market by value in 2018?
- What will be the size of the Indonesia pharmaceuticals market in 2023?
- What factors are affecting the strength of competition in the Indonesia pharmaceuticals market?
- How has the market performed over the last five years?
- How large is Indonesia’s pharmaceuticals market in relation to its regional counterparts?
'
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
PT Kalbe Farma Tbk
Novartis AG
Sanofi SA
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Indonesia pharmaceuticals market value: $ billion, 2014-18
Table 2: Indonesia pharmaceuticals market geography segmentation: $ billion, 2018
Table 3: Indonesia pharmaceuticals market share: % share, by value, 2018
Table 4: Indonesia pharmaceuticals market value forecast: $ billion, 2018-23
Table 5: PT Kalbe Farma Tbk: key facts
Table 6: PT Kalbe Farma Tbk: key financials ($)
Table 7: PT Kalbe Farma Tbk: key financials (IDR)
Table 8: PT Kalbe Farma Tbk: key financial ratios
Table 9: Novartis AG: key facts
Table 10: Novartis AG: key financials ($)
Table 11: Novartis AG: key financial ratios
Table 12: Sanofi SA: key facts
Table 13: Sanofi SA: key financials ($)
Table 14: Sanofi SA: key financials (€)
Table 15: Sanofi SA: key financial ratios
Table 16: Indonesia size of population (million), 2014-18
Table 17: Indonesia gdp (constant 2005 prices, $ billion), 2014-18
Table 18: Indonesia gdp (current prices, $ billion), 2014-18
Table 19: Indonesia inflation, 2014-18
Table 20: Indonesia consumer price index (absolute), 2014-18
Table 21: Indonesia exchange rate, 2014-18
List of Figures
Figure 1: Indonesia pharmaceuticals market value: $ billion, 2014-18
Figure 2: Indonesia pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 3: Indonesia pharmaceuticals market share: % share, by value, 2018
Figure 4: Indonesia pharmaceuticals market value forecast: $ billion, 2018-23
Figure 5: Forces driving competition in the pharmaceuticals market in Indonesia, 2018
Figure 6: Drivers of buyer power in the pharmaceuticals market in Indonesia, 2018
Figure 7: Drivers of supplier power in the pharmaceuticals market in Indonesia, 2018
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Indonesia, 2018
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Indonesia, 2018
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Indonesia, 2018
Figure 11: PT Kalbe Farma Tbk: revenues & profitability
Figure 12: PT Kalbe Farma Tbk: assets & liabilities
Figure 13: Novartis AG: revenues & profitability
Figure 14: Novartis AG: assets & liabilities
Figure 15: Sanofi SA: revenues & profitability
Figure 16: Sanofi SA: assets & liabilities
